|
|
|
Volumn 21, Issue 1, 2012, Pages 7-8
|
|
Oral/infusion cancer drug parity begins to raise health plan costs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
COST;
DRUG ADMINISTRATION ROUTE;
DRUG COST;
ECONOMICS;
FEE;
HEALTH INSURANCE;
HUMAN;
INSURANCE;
INTRAVENOUS DRUG ADMINISTRATION;
LEGAL ASPECT;
NEOPLASM;
NOTE;
ORAL DRUG ADMINISTRATION;
STANDARD;
UNITED STATES;
ADMINISTRATION, ORAL;
ANTINEOPLASTIC AGENTS;
DEDUCTIBLES AND COINSURANCE;
DRUG ADMINISTRATION ROUTES;
DRUG COSTS;
FEES, PHARMACEUTICAL;
HUMANS;
INFUSIONS, INTRAVENOUS;
INSURANCE BENEFITS;
INSURANCE, HEALTH;
NEOPLASMS;
UNITED STATES;
|
|
EID: 84856182260
PISSN: 10623388
EISSN: None
Source Type: Trade Journal
DOI: None Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
